Drug Profile
Research programme: anti-coronavirus monoclonal antibodies - Medarex/MBL
Latest Information Update: 02 May 2007
Price :
$50
*
At a glance
- Originator Medarex; University of Massachusetts Medical School
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 01 Jun 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the Viral Infections pharmacodynamics section
- 28 Apr 2004 Medarex and MBL have shipped a fully human anti-coronvairus antibody to Sinovac Biotech Co., Ltd., in China for preclinical testing
- 21 May 2003 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)